Jinyu Kang
About
Jinyu Kang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Jinyu Kang has authored 26 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Jinyu Kang's work include Prostate Cancer Treatment and Research (15 papers), PARP inhibition in cancer therapy (15 papers) and Radiation Therapy and Dosimetry (3 papers). Jinyu Kang is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), PARP inhibition in cancer therapy (15 papers) and Radiation Therapy and Dosimetry (3 papers). Jinyu Kang collaborates with scholars based in United States, United Kingdom and France. Jinyu Kang's co-authors include Fred Saad, Antoine Thiery-Vuillemin, Carrie A. Adelman, Joaquı́n Mateo, Johann S. de Bono, Joseph E. Burgents, Neal D. Shore, Karim Fizazi, Shahneen Sandhu and David Olmos and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Scientific Reports.
In The Last Decade
Jinyu Kang
25 papers receiving 2.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jinyu Kang United States | 13 | 1.4k | 1.3k | 799 | 593 | 232 | 26 | 2.2k | ||
| Maha Hussain United States | 11 | 1.4k 1.0× | 1.3k 0.9× | 942 1.2× | 562 0.9× | 232 1.0× | 20 | 2.3k | ||
| Eva Ciruelos Spain | 15 | 1.4k 1.0× | 1.5k 1.1× | 924 1.2× | 936 1.6× | 93 0.4× | 76 | 2.5k | ||
| Carol Peña France | 7 | 875 0.6× | 765 0.6× | 910 1.1× | 492 0.8× | 166 0.7× | 9 | 2.3k | ||
| Kim Chi Canada | 20 | 799 0.6× | 636 0.5× | 872 1.1× | 520 0.9× | 229 1.0× | 49 | 1.9k | ||
| Celine Wilke United States | 8 | 905 0.6× | 960 0.7× | 777 1.0× | 639 1.1× | 78 0.3× | 20 | 2.2k | ||
| Michael T. Schweizer United States | 33 | 2.2k 1.5× | 1.1k 0.8× | 929 1.2× | 746 1.3× | 444 1.9× | 144 | 3.1k | ||
| Janice M. Walshe Ireland | 19 | 2.1k 1.5× | 2.5k 1.9× | 414 0.5× | 1.2k 2.0× | 192 0.8× | 69 | 3.4k | ||
| Ryan J. Hartmaier United States | 24 | 948 0.7× | 936 0.7× | 878 1.1× | 687 1.2× | 77 0.3× | 63 | 2.1k | ||
| Shuanzeng Wei United States | 20 | 1.0k 0.7× | 504 0.4× | 908 1.1× | 540 0.9× | 114 0.5× | 73 | 2.1k | ||
| Florence Lerebours France | 29 | 692 0.5× | 1.4k 1.0× | 915 1.1× | 1.2k 2.0× | 322 1.4× | 97 | 2.6k |
Countries citing papers authored by Jinyu Kang
Since
Specialization
Citations
This map shows the geographic impact of Jinyu Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinyu Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinyu Kang more than expected).
Fields of papers citing papers by Jinyu Kang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jinyu Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinyu Kang. The network helps show where Jinyu Kang may publish in the future.
Co-authorship network of co-authors of Jinyu Kang
This figure shows the co-authorship network connecting the top 25 collaborators of Jinyu Kang. A scholar is included among the top collaborators of Jinyu Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinyu Kang. Jinyu Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Luo, Wenjing, Dahua Chen, Dong Jia, et al.. (2025). Identification of foam cell like M2 macrophages, AEBP1 biomarkers, and resveratrol as potential therapeutic in MASLD using Ecotyper and WGCNA. Scientific Reports. 15(1). 30233–30233.
2.
Lukashchuk, Natalia, Alan Barnicle, Carrie A. Adelman, et al.. (2023). Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Frontiers in Oncology. 13. 1162644–1162644.
3.
Kang, Jinyu, Shengtao Li, Yufei Song, et al.. (2022). Hepatocytic AP-1 and STAT3 contribute to chemotaxis in alphanaphthylisothiocyanate-induced cholestatic liver injury. Toxicology Letters. 373. 184–193.
4.
Saad, Fred, Antoine Thiery-Vuillemin, Paweł Wiechno, et al.. (2022). Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet Oncology. 23(10). 1297–1307.
5.
Matsubara, Nobuaki, Johann S. de Bono, David Olmos, et al.. (2021). Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. Journal of Clinical Oncology. 39(6_suppl). 27–27.
6.
Kang, Jinyu, Wentao Zheng, Jia Luo, et al.. (2021). Promoter CAG is more efficient than hepatocyte‑targeting TBG for transgene expression via rAAV8 in liver tissues. Molecular Medicine Reports. 25(1).
7.
Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Olaparib for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 382(22). 2091–2102.
8.
Hussain, Maha, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine. 383(24). 2345–2357.
9.
Bono, Johann S. de, Joaquı́n Mateo, Karim Fizazi, et al.. (2020). 610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Annals of Oncology. 31. S508–S508.
10.
Yang, Julin, et al.. (2020). PPARα mediates night neon light-induced weight gain: role of lipid homeostasis. Theranostics. 10(25). 11497–11506.
11.
Zhang, Xie, et al.. (2020). Safety and Efficacy of Through-the-Scope Placement of Colonic Self-expandable Metal Stents Without Fluoroscopic Guidance: A Retrospective Cohort Study. Surgical Laparoscopy Endoscopy & Percutaneous Techniques. 30(5). 430–434.
12.
Saad, Fred, Guilhem Roubaud, Giuseppe Procopio, et al.. (2020). Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.. Journal of Clinical Oncology. 38(15_suppl). 5538–5538.
13.
Thiery-Vuillemin, Antoine, Johann S. de Bono, Fred Saad, et al.. (2020). Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.. Journal of Clinical Oncology. 38(15_suppl). 5539–5539.
14.
Kang, Jinyu, et al.. (2019). Schisandrin B and Schisandrol B induce mouse CYP2b10 associated with CAR not PXR. Phytochemistry Letters. 35. 164–170.
15.
Clarke, Noel W., Andrew J. Armstrong, Antoine Thiery-Vuillemin, et al.. (2019). PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 37(7_suppl). TPS340–TPS340.
16.
Clarke, Noel W., Andrew J. Armstrong, Antoine Thiery-Vuillemin, et al.. (2019). PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). European Urology Supplements. 18(1). e1824–e1824.
17.
Yen, Chia-Jui, B. Markman, Yee Chao, et al.. (2017). Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC). Annals of Oncology. 28. iii54–iii54.
18.
Yuan, Yanyan, Yang Xi, Jiayi Chen, et al.. (2016). STAT3 stimulates adipogenic stem cell proliferation and cooperates with HMGA2 during the early stage of differentiation to promote adipogenesis. Biochemical and Biophysical Research Communications. 482(4). 1360–1366.
19.
Cicinnati, Vito R., Jinyu Kang, Monika Lindemann, et al.. (2009). Interferon-α Differentially Affects Homeostasis of Human Plasmacytoid and Myeloid Dendritic Cells. Journal of Interferon & Cytokine Research. 29(3). 145–160.
20.
Cicinnati, Vito R., Jinyu Kang, Georgios C. Sotiropoulos, et al.. (2008). Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. Journal of General Virology. 89(5). 1243–1253.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maha Hussain Breakdown of academic impact, for papers by Eva Ciruelos Breakdown of academic impact, for papers by Carol Peña Breakdown of academic impact, for papers by Kim Chi Breakdown of academic impact, for papers by Celine Wilke Breakdown of academic impact, for papers by Michael T. Schweizer Breakdown of academic impact, for papers by Janice M. Walshe Breakdown of academic impact, for papers by Ryan J. Hartmaier Breakdown of academic impact, for papers by Shuanzeng Wei Breakdown of academic impact, for papers by Florence Lerebours